Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis.
| Title: | Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis. |
|---|---|
| Authors: | Jeffreys SA; Centre of Circulating Tumour Cell Diagnostics and Research, Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia.; School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.; Becker TM; Centre of Circulating Tumour Cell Diagnostics and Research, Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia.; South Western Sydney Clinical School, University of New South Wales, Liverpool Hospital, Liverpool, NSW, Australia.; Khan S; Department of Medical Oncology, Bankstown Cancer Centre, Bankstown, NSW, Australia.; Soon P; Centre of Circulating Tumour Cell Diagnostics and Research, Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia.; South Western Sydney Clinical School, University of New South Wales, Liverpool Hospital, Liverpool, NSW, Australia.; Department of Surgery, Bankstown Hospital, Bankstown, NSW, Australia.; Neubauer H; Department of Obstetrics and Gynaecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.; de Souza P; Centre of Circulating Tumour Cell Diagnostics and Research, Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia.; School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.; South Western Sydney Clinical School, University of New South Wales, Liverpool Hospital, Liverpool, NSW, Australia.; Powter B; Centre of Circulating Tumour Cell Diagnostics and Research, Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia. |
| Source: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Jun 17; Vol. 13, pp. 895729. Date of Electronic Publication: 2022 Jun 17 (Print Publication: 2022). |
| Publication Type: | Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; Journal Article |
| Language: | English |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| MeSH Terms: | Breast Neoplasms*/diagnosis ; Breast Neoplasms*/genetics ; Breast Neoplasms*/metabolism ; Cyclin D1*/genetics ; Cyclin D1*/metabolism; Postmenopause/genetics ; Receptors, Estrogen/genetics ; Receptors, Estrogen/metabolism ; Gene Amplification ; Humans ; Prognosis ; Female |
| Abstract: | Background: Up to 80% of breast cancers (BCa) are estrogen receptor positive and current treatments target the estrogen receptor (endocrine therapies) and/or CDK4/6 (CDK4/6 inhibitors). CCND1 encodes the protein cyclin D1, responsible for regulation of G1 to S phase transition in the cell cycle. CCND1 amplification is common in BCa and contributes to increased cyclin D1 expression. As there are signalling interactions between cyclin D1 and the estrogen receptor, understanding the impact of CCND1 amplification on estrogen receptor positive patients' disease outcomes, is vital. This review aims to evaluate CCND1 amplification as a prognostic and predictive biomarker in BCa.; Materials and Methods: Publications were retrieved from the databases: PubMed, MEDLINE, Embase and Cochrane library. Exclusion criteria were duplication, publication type, non-English language, in vitro and animal studies, not BCa, male BCa, premenopausal BCa, cohort size |
| Competing Interests: | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Curr Breast Cancer Rep. 2012 Sep;4(3):171-173. (PMID: 22924091); J BUON. 2017 Sep-Oct;22(5):1209-1216. (PMID: 29135104); Mol Cell Biol. 1997 Sep;17(9):5338-47. (PMID: 9271411); Turk J Med Sci. 2018 Aug 16;48(4):759-767. (PMID: 30119151); Oncogene. 2006 Mar 2;25(9):1367-77. (PMID: 16331275); Expert Rev Mol Diagn. 2018 Mar;18(3):259-277. (PMID: 29431533); Lancet Glob Health. 2020 Aug;8(8):e1027-e1037. (PMID: 32710860); Oncogene. 2007 Oct 25;26(49):6997-7005. (PMID: 17486065); Breast Cancer Res Treat. 2017 Aug;164(3):667-678. (PMID: 28528450); Breast Cancer Res. 2012 Apr 04;14(2):R57. (PMID: 22475046); Ann Intern Med. 2013 Feb 19;158(4):280-6. (PMID: 23420236); Am J Transl Res. 2016 Jan 15;8(1):142-53. (PMID: 27069548); Mod Pathol. 1998 Feb;11(2):155-68. (PMID: 9504686); Breast Cancer Res Treat. 2012 Nov;136(1):161-8. (PMID: 22976805); Breast Cancer Res Treat. 2009 Jan;113(1):75-82. (PMID: 18240019); Clin Cancer Res. 1996 Jul;2(7):1177-84. (PMID: 9816285); Cancer Lett. 2019 Oct 1;461:21-30. (PMID: 31229512); Clin Transl Oncol. 2021 Apr;23(4):874-881. (PMID: 32880048); Am J Clin Pathol. 2005 Jan;123(1):21-7. (PMID: 15762276); Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230); Br J Cancer. 2002 Feb 12;86(4):580-6. (PMID: 11870541); Cells. 2019 Apr 06;8(4):. (PMID: 30959874); Mol Cell Biol. 2004 Aug;24(16):7260-74. (PMID: 15282324); Oncology (Williston Park). 2009 Feb;23(2):133-42. (PMID: 19323294); Trials. 2007 Jun 07;8:16. (PMID: 17555582); Am J Pathol. 1997 Feb;150(2):705-11. (PMID: 9033283); Cells. 2020 Sep 11;9(9):. (PMID: 32932819); Pathol Res Pract. 2021 Jun;222:153430. (PMID: 33839437); Breast J. 2007 Jul-Aug;13(4):337-45. (PMID: 17593037); Front Endocrinol (Lausanne). 2019 Aug 21;10:573. (PMID: 31496995); Int J Cancer. 2010 Jul 15;127(2):355-60. (PMID: 19904758); JCO Oncol Pract. 2022 Mar;18(3):211-216. (PMID: 34637342); Int J Cancer. 1996 Aug 22;69(4):247-53. (PMID: 8797862); Cancer Res. 2004 Dec 1;64(23):8534-40. (PMID: 15574759); Mol Cell. 2019 May 16;74(4):758-770.e4. (PMID: 30982746); Sci Transl Med. 2017 Aug 9;9(402):. (PMID: 28794284); Cells. 2020 Dec 09;9(12):. (PMID: 33317149); PLoS One. 2017 Nov 15;12(11):e0188068. (PMID: 29140993); Diagn Mol Pathol. 2010 Dec;19(4):187-93. (PMID: 21052003); Asian Pac J Cancer Prev. 2015;16(17):7997-8002. (PMID: 26625832); Histopathology. 2008 May;52(6):698-705. (PMID: 18393977); Neoplasma. 2010;57(4):325-32. (PMID: 20429623); Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275); Mod Pathol. 2006 Jul;19(7):999-1009. (PMID: 16648863); Breast Cancer Res Treat. 2010 Jun;121(3):575-89. (PMID: 19688261); Breast Cancer. 2016 Jan;23(1):111-119. (PMID: 24862872); Mol Cell Biol. 2010 Jun;30(12):3111-25. (PMID: 20404095); Cancer Res. 2005 Sep 1;65(17):8009-16. (PMID: 16140974); Mod Pathol. 2010 Mar;23(3):392-403. (PMID: 20062009); Breast Cancer Res Treat. 2010 Jun;121(2):347-54. (PMID: 19636701); Hum Pathol. 2020 Aug;102:94-103. (PMID: 32445652); Eur Spine J. 2020 Jun;29(6):1318-1327. (PMID: 32328791); BMC Cancer. 2018 Jul 24;18(1):761. (PMID: 30041599); Breast Cancer Res Treat. 2008 May;109(2):325-35. (PMID: 17653856); Genet Mol Biol. 2019 Feb 28;42(1):26-31. (PMID: 30816904); Breast Cancer Res. 2019 Feb 28;21(1):34. (PMID: 30819233); Cell Oncol (Dordr). 2014 Apr;37(2):107-18. (PMID: 24573687); BMC Cancer. 2010 Aug 24;10:458. (PMID: 20735841); Breast Cancer Res Treat. 2020 Jan;179(2):387-401. (PMID: 31620934); Clin Cancer Res. 1999 Aug;5(8):2069-76. (PMID: 10473088); Breast Cancer Res Treat. 2013 Jun;139(2):329-39. (PMID: 23670132) |
| Contributed Indexing: | Keywords: CCND1; amplification; biomarker; breast cancer; cyclin D1; meta-analysis; systematic review |
| Substance Nomenclature: | 0 (CCND1 protein, human); 0 (Receptors, Estrogen); 136601-57-5 (Cyclin D1) |
| Entry Date(s): | Date Created: 20220705 Date Completed: 20220706 Latest Revision: 20260427 |
| Update Code: | 20260428 |
| PubMed Central ID: | PMC9249016 |
| DOI: | 10.3389/fendo.2022.895729 |
| PMID: | 35784572 |
| Database: | MEDLINE |
Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; Journal Article